Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients.

[1]  J. Meigs,et al.  Tumors of the Female Pelvic Organs , 2013 .

[2]  Jeffrey J H Low,et al.  Epithelial ovarian cancer , 2018, An Atlas of Gynecologic Oncology.

[3]  G. Kenter,et al.  EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA) , 2008 .

[4]  W. Cliby,et al.  Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. , 2008, Gynecologic oncology.

[5]  I Vergote,et al.  Timing of debulking surgery in advanced ovarian cancer , 2008, International Journal of Gynecologic Cancer.

[6]  R. Barakat,et al.  The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. , 2008, Gynecologic oncology.

[7]  R. Barakat,et al.  Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. , 2006, Gynecologic oncology.

[8]  W. Cliby,et al.  Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. , 2006, Gynecologic oncology.

[9]  P. Neven,et al.  Neoadjuvant chemotherapy for ovarian cancer. , 2005, Oncology.

[10]  W. Cliby,et al.  Diaphragm resection for ovarian cancer: technique and short-term complications. , 2004, Gynecologic oncology.

[11]  D. Atallah,et al.  Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. , 2003, Journal of the American College of Surgeons.

[12]  N. Spirtos,et al.  Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. , 2003, Gynecologic oncology.

[13]  E. Trimble,et al.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Spirtos,et al.  What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? , 2001, Gynecologic oncology.

[15]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[16]  C. Pomel,et al.  Cytoreductive surgery for advanced stages of ovarian cancer. , 2000, Seminars in surgical oncology.

[17]  P. V. van Dam,et al.  Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. , 1998, Gynecologic oncology.

[18]  He-jing Wang,et al.  Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. , 1998, Gynecologic oncology.

[19]  I. Vergote,et al.  The feasibility of open laparoscopy in gynecologic-oncologic patients. , 1997, Gynecologic oncology.

[20]  J. Horiot,et al.  A glossary for reporting complications of treatment in gynecological cancers. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Michael D. Vose,et al.  Modeling genetic algorithms with Markov chains , 1992, Annals of Mathematics and Artificial Intelligence.

[22]  C. Griffiths,et al.  Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. , 1990, Gynecologic oncology.

[23]  E. van der Velde,et al.  The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. , 1988, Gynecologic oncology.

[24]  D. Rubin,et al.  Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 1985 .

[25]  Griffiths Ct.  Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. , 1975 .

[26]  W. Cliby,et al.  Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. , 2006, Gynecologic oncology.